Recent Quotes
My Watchlist
Indicators
Local Stocks
Local Stocks
Energy Stocks
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Ligand Pharm (NQ: LGND )

142.62 USD +7.73 (+5.73%)
Official Closing Price Updated: 7:44 PM EST, Jan 22, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All news about Ligand Pharm

< Previous 1 2 3 4 5 6 7 8 9
...
44 45 Next >
Notable Tuesday Option Activity: ACI, LGND, COUP
Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Albertsons Companies Inc (ACI), where a total volume of 16,547 contracts has been... 
Tags Stocks
From Market News Video
Ligand Provides Highlights from Today’s Investor Day Event
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced that at today’s virtual Investor Day event its senior management reviewed recent business progress and provided a financial growth outlook.... 
From Business Wire News Releases
Analysts Anticipate AFSM To Hit $21
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and... 
Tags ETFs
From ETF Channel
Ligand’s Third Quarter Financial Results to be Reported October 30th
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) provided today details of its plans to report third quarter 2020 financial results on October 30, 2020. Ligand’s CEO John Higgins, President and COO... 
From Business Wire News Releases
Week In Review: Curon Bio Acquires Rights To Lymphoma Drug In $150 Million Deal
Curon Biopharma, a Shanghai clinical-stage in-licensing company, acquired China rights to Tenalisib, a dual PI3K delta and gamma inhibitor, from Rhizen Pharma. Rhizen will receive milestone payments... 
Tags Stocks / Equities Pharma/Biotech Healthcare
From Blogs - TalkMarkets
Week in Review: Curon Bio Acquires Rights to Lymphoma Drug in $150 Million Deal
Deals and Financings Shanghai Curon Biopharma acquired China rights to a treatment for a novel lymphoma drug from Rhizen Pharma of Switzerland in a $149.5 million deal; EdiGene of Beijing raised $67... 
From ChinaBio® Today
Week in Review: Curon Bio Acquires Lymphoma Drug Rights in $150 Million Deal
Deals and Financings Shanghai Curon Biopharma acquired China rights to a treatment for a novel lymphoma from Rhizen Pharma of Switzerland in a $149.5 million deal; EdiGene of Beijing raised $67 million... 
From ChinaBio® Today
Sermonix Doses First Patient in Phase 2 Clinical Trial Collaboration Studying Lasofoxifene in Combination With Eli Lilly and Company’s Abemaciclib
Working with Tempus to identify and enroll trial participants, study will evaluate safety of combination for treatment of women with ER+/HER2- metastatic breast cancer and an ESR1 mutation 
From GlobeNewswire News Releases
Ligand to Divest Vernalis Research Operations
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces the sale of Ligand’s Vernalis research operations and internal programs to HitGen Inc. (SHA: 688222) for $25 million in cash. Under the... 
From Business Wire News Releases
HitGen Pays $25 Million to Acquire Vernalis, a UK Discovery CRO, from Ligand
HitGen will acquire Vernalis Limited, a Cambridge , UK CRO, from Ligand Pharma for $25 million. HitGen, a Chengdu small molecule drug development CRO, said its operations are a good fit with Vernalis'... 
From ChinaBio® Today
HitGen to Acquire Vernalis, a Leader in Structure-Based Drug Discovery
HITGEN (688222.SH) announces it has entered into a definitive agreement with Ligand Pharmaceuticals Inc. (NASDAQ: LGND) to acquire Vernalis (R&D) Limited, Cambridge, UK-based world leaders in fragment... 
From Business Wire News Releases
Ligand: The Small Cap Powering Gilead's Remdesivir
President Donald Trump has taken several treatments to combat the coronavirus diagnosis he received last week. Among them are an ... 
Tags BAX Covid/19 Market News
From Benzinga
Analyst Favorites With Strong Buyback Activity: Ligand Pharmaceuticals Ranks As a Top Pick
A study of analyst recommendations at the major brokerages shows that Ligand Pharmaceuticals Inc (LGND) is the #64 broker analyst pick among those stocks screened by The Online Investor for strong... 
Tags Stocks
From Market News Video
Ligand to Host Virtual Investor Day on October 20th
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces the Company will be hosting a virtual Investor Day on Tuesday, October 20th from 11:00 a.m. ET to approximately 1:00 p.m. ET. Presenting... 
From Business Wire News Releases
Ligand Completes Acquisition of Pfenex Inc.
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announced it has completed its tender offer for all outstanding shares of Pfenex Inc. for $437.5 million in cash, plus one non-transferable... 
From Business Wire News Releases
Sermonix Pharmaceuticals Partners With Exactis Innovation for ELAINE 1 Clinical Trial Sites in Canada
Study of lasofoxifene versus fulvestrant in patients with metastatic breast cancer will include seven precision-medicine Exactis Network study locations 
From GlobeNewswire News Releases
Ligand Announces Expiration of Tender Offer for Shares of Pfenex Inc.
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announced that its tender offer to purchase any and all issued and outstanding shares of common stock of Pfenex Inc. (NYSE American: PFNX) at an... 
From Business Wire News Releases
CStone, Pfizer Enter into Strategic Collaboration to Address Oncological Needs in China
CStone Pharmaceuticals (“CStone”, HKEX: 2616)] and Pfizer Investment Co. Ltd. ("Pfizer Investment") and Pfizer Corporation Hong Kong Limited ("Pfizer Hong Kong") (both of which are subsidiaries of... 
From Business Wire News Releases
10 Biggest Price Target Changes For Tuesday
Morgan Stanley lifted the price target on Equinix, Inc. (NASDAQ: EQIX) from $670 to $712. Equinix shares rose 1.8% to close at ... 
Tags Market News Price Target HRC
From Benzinga
Notable Wednesday Option Activity: JBL, IOSP, LGND
Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Jabil Inc (JBL), where a total of 16,146 contracts have traded so far, representing... 
Tags Stocks
From Market News Video
Ligand Announces its Captisol Business is Positioned for Major Growth and Forecasts 2021 Captisol Material Sales of $200 Million
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces that recent new contracting with partners and investments in manufacturing capacity have contributed to its Captisol business operating at... 
From Business Wire News Releases
How The Parts Add Up: FTLB Headed For $22
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and... 
Tags ETFs
From ETF Channel
Ligand Expands OmniAb® Antibody Discovery Platform Through the Acquisitions of xCella Biosciences and Taurus Biosciences
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces the acquisition of two privately held companies that strengthen and complement its OmniAb® technology platform. Ligand acquired xCella... 
From Business Wire News Releases
The Week Ahead In Biotech: Focus On Mallinckrodt FDA Decision, Conference Presentations
After remaining steady in the first three sessions of the week ended September 4, biotech stocks pulled back along with the broader market in a tech-induced sell-off. Barring anything COVID-19-related,... 
Tags Pharma/Biotech Stocks / Equities
From Blogs - TalkMarkets
The Week Ahead In Biotech: Focus On Mallinckrodt FDA Decision, Conference Presentations
After remaining steady in the first three sessions of the week ended Sept. 4, biotech stocks pulled back along with the broader market ... 
Tags Market News Top Stories NBIX
From Benzinga
Ligand Pharmaceuticals Management to Present at the H.C. Wainwright 22nd Annual Global Investment Virtual Conference
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announced that senior management will present at an upcoming investor conference. 
From Business Wire News Releases
Ligand Commences Previously Announced Cash Tender Offer to Acquire Pfenex Inc.
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced today that its wholly-owned subsidiary, Pelican Acquisition Sub, Inc. (the “Purchaser”), is commencing a tender offer to purchase all... 
From Business Wire News Releases
Ligand OmniAb® Partner Immunovant Announced Positive Topline Results from Multicenter, Placebo-Controlled Phase 2a Trial of IMVT-1401 in Myasthenia Gravis
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) OmniAb® partner Immunovant, Inc. (NASDAQ: IMVT) announced positive topline results from ASCEND MG, a Phase 2a study of OmniAb-derived IMVT-1401 in... 
From Business Wire News Releases
Ligand Announces Amgen’s KYPROLIS® Approved by FDA as Combination Regimen with DARZALEX® and Dexamethasone in Once- and Twice-Weekly Dosing Regimens for Patients with Relapsed/Refractory Multiple Myel
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces that a major Captisol customer Amgen (NASDAQ: AMGN) has received U.S. Food and Drug Administration (FDA) approval for the expansion of the... 
From Business Wire News Releases
Analysts See 10% Gains Ahead For SMLV
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and... 
Tags ETFs
From ETF Channel
< Previous 1 2 3 4 5 6 7 8 9
...
44 45 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.